Skip to content

Clinical trials

Observational Radiation Injuries trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Radiation Injuries Phase: Observational Clear all

97 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20012
20031
20041
20052
20086
20091
20101
20111
20123
20133
20142
20152
20165
20177
20188
20199
20206
20216
20228
20235
20243
20254
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed37
Recruiting23
Unknown status21
Active, not recruiting7
Withdrawn4
Not yet recruiting2
Terminated2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of Aarhus5
Bernardino Clavo, MD, PhD3
National Taiwan University Hospital3
AHS Cancer Control Alberta2
Case Comprehensive Cancer Center2
Centre hospitalier de l'Université de Montréal (CHUM)2
Chinese Academy of Medical Sciences2
IRCCS Azienda Ospedaliero-Universitaria di Bologna2
King Hussein Cancer Center2
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Radiation Injuries97
Head and Neck Neoplasms15
Neoplasms13
Breast Neoplasms12
Brain Neoplasms9
Prostatic Neoplasms7
Lung Neoplasms5
Esophageal Neoplasms4
Anxiety Disorders3
Carcinoma, Non-Small-Cell Lung3

Trials

Showing 51 to 75 of 97. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.